Alzheimer’s Disease Trials (AD)

---

The following are ongoing Alzheimer’s Disease clinical trials enrolling patients:

Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer’s Disease (COGNITE)

A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer’s Disease

A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer’s Disease_ (MissionAD2)

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (Generation S1)

Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer’s Disease (AD)

A Study of LY3303560 in Participants With Early Symptomatic Alzheimer’s Disease

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (Generation S2)

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer’s Disease.

A Study of LY3002813 and LY3202626 in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ)

A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer’s Disease

Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer’s Disease (BUENA)